Health ministry blow to Sun Pharmaceuticals
The Union health ministry asked the Drug Controller General of India office to inspect the drug manufacturing plant of Sun pharma
NEW DELHI: Two days after the US Food and Drug Administration (FDA) banned imports from Indian generic drug maker Sun Pharmaceutical Industries Ltd’s plant at Karkhadi in Gujarat, the Union health ministry asked the Drug Controller General of India office to inspect the drug manufacturing plant of Sun pharmaceutical industries and lift samples for independent testing.
Indian drug manufacturing units have been under “strict” scrutiny for long now. Earlier, drug manufacturing plants of Ranbaxy were closed for import after they were found to be not complying with the good manufacturing practices.
On Wednesday, the FDA issued an “import alert” against the Sun pharma unit. The agency defines such a sanction as something that results in the detention without physical examination of drugs from firms that haven’t complied with good manufacturing practices.
“Action will be taken against the firm if it is found not complying with standards. A team of experts will soon visit the unit and take some samples for testing,” said a senior official in the health ministry.